D-Sight
D-Sight is a Barcelona-based clinical-stage biotech spun out of VHIR developing first-in-class DPP-IV inhibitor neuroprotective eye drops for early-stage diabetic retinopathy and glaucoma, targeting healthcare providers via future pharmaceutical distribution channels.
- Company typePrivate
- Founded2023
- HeadquartersBarcelona, Spain
- Headcount1–10
- GTM typeB2B
- OfferingServices
What D-Sight does
D-Sight S.L is a clinical-stage biopharmaceutical spin-off from the Vall d'Hebron Research Institute (VHIR), headquartered in Barcelona, Spain, and founded in 2023. The company is developing a platform of first-in-class neuroprotective eye drops based on repurposed DPP-IV inhibitors (sitagliptin and saxagliptin) that increase intraretinal GLP-1 levels to deliver dual neurotrophic and vasculotrophic action in retinal neurodegenerative disease, without altering systemic blood glucose. The lead program targets early-stage diabetic retinopathy, with additional programs covering advanced diabetic retinopathy and glaucoma neuroprotection.
The core technology is a proprietary topical ocular formulation of known DPP-IV inhibitor molecules, protected by a patent family filed in 22 countries. D-Sight operates in a lean team configuration — three co-founders (CEO Carla Maté Goldar, CMO Dr. Rafael Simó Canonge, CSO Dr. Cristina Hernández Pascual) plus a postdoctoral researcher — supported by the VHIR ecosystem and a manufacturing partnership with the CDMO Famar Group for clinical-batch production. The company has accumulated approximately €3 million in private venture funding (€1M seed from Clave Capital in 2023, €2M round led by Clave Capital in February 2026 with Prous Institute, ICF, and BioAngels Club), complemented by €1.5 million in non-dilutive public grants from MICIU/AEI, and is preparing for first-in-human clinical validation in 2026.
The business model is a sales-led pharmaceutical commercialization pathway: D-Sight is pre-revenue and not yet selling product, with planned future revenue derived from prescription sales of regulatory-approved neuroprotective eye drops to ophthalmologists, hospitals, and pharmaceutical distributors treating diabetic retinopathy and glaucoma. The company intends to advance through clinical development and is preparing a Series A to fund Phase II studies.
D-Sight firmographics
Firmographics- Name
- D-Sight
- Legal name
- D-SIGHT S.L
- Website
- https://dsight.es
- Company type
- Private
- Founded year
- 2023
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- D-Sight is a Barcelona-based clinical-stage biotech spun out of VHIR developing first-in-class DPP-IV inhibitor neuroprotective eye drops for early-stage diabetic retinopathy and glaucoma, targeting healthcare providers via future pharmaceutical distribution channels.
- Ownership category
- akta.pro rank
D-Sight industry classification
Industry- Product category
- Ophthalmic Pharmaceuticals
- NAICS
- Scientific Research and Development Services (5417)
- SIC
- Ophthalmic Goods (3851)
- akta.pro primary industry
- Ocular Drug Delivery Devices (Eye Droppers/Inserts) (HLAHAIAL)
- akta.pro secondary industry
- Ophthalmology Specialty Pharmaceuticals (HLAIACAK)
Keywords
Where D-Sight is headquartered
LocationHeadquarters
- HQ city
- Barcelona
- HQ country
- Spain
- HQ region
- Europe
Offices1 record
Markets served
D-Sight business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Pharmaceutical Drug Sales: Pre-revenue clinical-stage biotech. The company is developing neuroprotective eye drops for diabetic retinopathy and glaucoma. Revenue will be generated through sales of prescription pharmaceutical products upon regulatory approval.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
D-Sight product offering
Product offeringCore offering
D-Sight develops first-in-class neuroprotective eye drops based on DPP-IV inhibitors (sitagliptin and saxagliptin) for the early-stage treatment of retinal neurodegenerative diseases, primarily diabetic retinopathy and glaucoma. The therapy is administered as non-invasive topical ocular drops that increase intraretinal GLP-1 levels, delivering neurotrophic and vasculotrophic effects without altering blood glucose. The company is currently clinical-stage, with first human clinical validation planned for 2026.
Product overview
D-Sight is developing a platform of first-in-class neuroprotective eye drops based on DPP-IV inhibitors (sitagliptin and saxagliptin) for the treatment of retinal neurodegenerative diseases. The core product is a non-invasive, self-administrable eye drop therapy that prevents vision loss by targeting neurodegeneration at early disease stages. The product portfolio includes treatments for early-stage diabetic retinopathy (lead program in Phase I/II preparation), advanced diabetic retinopathy, and glaucoma. The technology works by inhibiting DPP-IV enzyme to increase intraretinal GLP-1 levels, executing dual neurotrophic and vasculotrophic action without affecting blood glucose levels.
Differentiator
Problem solved
Functional benefit
Products and services
- Neuroprotective Eye Drops (DPP-IV Inhibitor Platform) First-in-class neuroprotective eye drops based on DPP-IV inhibitors (sitagliptin and saxagliptin) designed to prevent and treat retinal diseases at their earliest stages by increasing intraretinal GLP-1 content and executing dual neurotrophic and vasculotrophic action. Intended for prescription use by ophthalmologists and healthcare providers upon regulatory approval.
- Early-Stage Diabetic Retinopathy Treatment Lead clinical-stage drug candidate using topical ocular administration of DPP-IV inhibitors to prevent neurodegeneration and early microvascular alterations in early-stage diabetic retinopathy. Non-invasive, self-administrable treatment that does not alter blood glucose levels, intended for ophthalmology and endocrinology specialists.
- Glaucoma Neuroprotective Drug Candidate Preclinical neuroprotective drug candidate for glaucoma added to D-Sight's pipeline, addressing an area of high unmet medical need where current therapies remain limited. Intended for prescription use by ophthalmologists once development and regulatory milestones are achieved.
- Advanced-Stage Diabetic Retinopathy Treatment Pipeline drug candidate targeting advanced stages of diabetic retinopathy, complementing D-Sight's early-stage treatment approach within the DPP-IV inhibitor platform. Intended for prescription use by ophthalmologists treating more advanced diabetic retinopathy patients.
Quantifiable outcome
- 2.2 billion people living with vision impairment worldwide; 186 million adults suffering diabetic retinopathy; 76 million adults living with glaucoma
Companies that use D-Sight
Customer profileSegments1 record
Ideal customer profiles1 record
D-Sight technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
D-Sight partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- Famar GroupcoreStrategic partnership with Famar Group, a European contract manufacturing and development organization serving the pharmaceutical industry. This collaboration will accelerate the development and production of clinical batches for D-Sight's eye drops solution intended for the treatment of early stages of diabetic retinopathy.
- Vall d'Hebron Research Institute (VHIR)coreParent research institution from which D-Sight was spun off. D-Sight is a clinical-stage spin-off from VHIR, translating cutting-edge neuroscience research into novel ophthalmic solutions.
Scale indicators4 records
Recent moves7 records
Expansion highlights5 records
D-Sight competitors and assessment
Company assessmentDirect peers
- Oxurion: Clinical-stage European biotech developing therapeutics for diabetic retinopathy and other retinal vascular diseases. Most directly comparable to D-Sight in indication focus and clinical-stage status, though Oxurion has historically pursued anti-VEGF/kinase inhibitor approaches rather than neuroprotection.
- Kodiak Sciences: Clinical-stage biotech developing novel therapies for retinal diseases including diabetic macular edema and AMD. Comparable as a retinal-focused clinical-stage company with Phase II/III assets, though Kodiak's ABC platform targets VEGF-pathway modulation.
- EyePoint Pharmaceuticals: Commercial-stage ocular drug delivery company developing sustained-release treatments for retinal diseases. Comparable given shared focus on ophthalmic drug delivery innovation, though EyePoint uses bioerodible implants rather than topical eye drops.
Emerging players
- Adverum Biotechnologies: Clinical-stage gene therapy company targeting wet AMD and diabetic retinopathy with intravitreal AAV-based therapeutics. Comparable as a retinal-disease-focused clinical biotech, but uses a different modality (gene therapy) and delivery route (intravitreal injection).
- Aerpio Pharmaceuticals: Clinical-stage biotech that has investigated tie-2 activation and other mechanisms for diabetic retinopathy and glaucoma. Comparable indication overlap though different therapeutic mechanisms.
- Alimera Sciences: Specialty ophthalmology company commercializing Iluvien (sustained-release intravitreal implant) for diabetic macular edema. Comparable as a focused ophthalmology commercial player addressing diabetic retinopathy with innovative delivery.
Broad incumbents
- Regeneron Pharmaceuticals: Large biopharmaceutical company whose Eylea (aflibercept) is the market-leading anti-VEGF therapy for diabetic retinopathy and related retinal diseases. Defines the competitive benchmark D-Sight must outperform on safety, cost, or earlier-stage intervention.
- Bayer (Ophthalmology): Co-developer and global commercializer of Eylea, dominating the diabetic retinopathy treatment landscape. Represents both a competitive threat and a potential strategic acquirer/licensee for D-Sight's neuroprotective platform.
- Roche/Genentech: Developer of Lucentis (ranibizumab), one of the foundational anti-VEGF therapies for diabetic retinopathy and AMD. A major incumbent that any neuroprotective entrant must position against in clinical and commercial terms.
- Novartis (Ophthalmology): Markets Beovu (brolucizumab) for diabetic macular edema and related retinal indications. Represents a large-pharma competitor with deep ophthalmology commercial infrastructure.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks6 records
Key highlights7 records
Customer concentration
D-Sight social profiles
Digital presenceD-Sight compliance and trust
Trust signalCompliance1 record
D-Sight financial estimates
Financial estimateRevenue estimate
Valuation estimate
D-Sight leadership team
Management profileNumber of profiles
Profiles4 records
D-Sight funding detail
Funding detailFunding overview
Funding rounds2 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
D-Sight M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about D-Sight
What does D-Sight do?
D-Sight develops first-in-class neuroprotective eye drops based on DPP-IV inhibitors (sitagliptin and saxagliptin) for the early-stage treatment of retinal neurodegenerative diseases, primarily diabetic retinopathy and glaucoma. The therapy is administered as non-invasive topical ocular drops that increase intraretinal GLP-1 levels, delivering neurotrophic and vasculotrophic effects without altering blood glucose. The company is currently clinical-stage, with first human clinical validation planned for 2026.
Is D-Sight a public or private company?
D-Sight is a private company. It is classified as venture growth investor backed and is currently operating.
When was D-Sight founded?
D-Sight was founded in 2023. It employs 1 to 10 people.
Where is D-Sight based?
D-Sight is headquartered in Barcelona, Spain, in the Europe region.
How does D-Sight make money?
One revenue line is on record: pharmaceutical Drug Sales.
Who are D-Sight's main competitors?
Direct peers on record are Oxurion, Kodiak Sciences and EyePoint Pharmaceuticals. Emerging players are Adverum Biotechnologies, Aerpio Pharmaceuticals and Alimera Sciences. Broad incumbents are Regeneron Pharmaceuticals, Bayer (Ophthalmology), Roche/Genentech and Novartis (Ophthalmology).
Does D-Sight have an API?
No public API is recorded for D-Sight.
What industry is D-Sight in?
D-Sight's product category is Ophthalmic Pharmaceuticals. Its primary akta.pro industry code is HLAHAIAL, Ocular Drug Delivery Devices (Eye Droppers/Inserts), with a secondary code of HLAIACAK, Ophthalmology Specialty Pharmaceuticals. Its NAICS code is 5417 and its SIC code is 3851.